Delving into the Latest Updates on Forest Hills Partners Hong Kong Limited with Synapse

Overview

Tags

Nervous System Diseases

Endocrinology and Metabolic Disease

Congenital Disorders

Small molecule drug

Synthetic peptide

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Nervous System Diseases	9
Endocrinology and Metabolic Disease	7

Top 5 Drug Type	Count

Small molecule drug	5
Synthetic peptide	2
Antibody	1
Monoclonal antibody	1

Oscillator strengths for 140 lines of Th II were calculated from the data in the NBS Tables of Spectral-Line Intensities.The relative level populations were determined from measurements of lines of Fe I in the same light source.The absolute scale is determined by means of the lifetime of the level at 24874 cm^-1 recently measured by T. Andersen and A. P. Petkov (1975).The uncertainty in the present results is ≈35%.

100 Deals associated with Forest Hills Partners Hong Kong Limited

Login to view more data

100 Translational Medicine associated with Forest Hills Partners Hong Kong Limited

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 09 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

9

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

FHL-701	Parkinson Disease More	Preclinical
FHL-301	Alzheimer Disease More	Preclinical
FHL-201	Parkinson Disease More	Preclinical
FHL-401	Alzheimer Disease More	Preclinical
FHL-801	Parkinson Disease More	Preclinical